
This Massachusetts man became a millionaire twice in one night – thanks to a lucky lottery mistake
Paul Corcoran of Fitchburg, a small city in north-central Massachusetts, planned to play in the July 9 Powerball drawing. He had initially purchased a multi-draw ticket covering seven games but mistakenly believed the final drawing on that ticket had passed, according to a news release from Powerball.
So, less than 10 minutes away from the first store where he bought a ticket, he picked up a second ticket for seven Powerball drawings — one that also included the July 9 drawing.
That simple mistake earned him a second chance at the $217 million jackpot, according to the Massachusetts State Lottery.
Both winning Powerball tickets matched all five white balls drawn on July 9 – 5, 9, 25, 28 and 69, earning Corcoran $1 million, pre-tax, per winning ticket, according to Powerball.
Corcoran's numbers just missed the red Powerball, lucky number 5, falling one number short of the full jackpot. He said he's been playing those same random numbers 'for quite some time' when he claimed his winnings at the Massachusetts State Lottery headquarters, a state lottery spokesperson told CNN.
Both stores where Corcoran bought the tickets – a Market Basket supermarket in Fitchburg and a Country Farms convenience store in Leominster – will receive a payout of $10,000, the lottery spokesperson said.
The winning tickets were the first Powerball tickets worth $1 million sold in Fitchburg and Leominster, Massachusetts, according to the Massachusetts State Lottery.
Corcoran told lottery officials his double win feels good, but he does not yet have plans for what he will do with his winnings.
The odds of winning the Powerball jackpot are 1 in 292.2 million. The next Powerball drawing is July 21 with an estimated jackpot of $308 million.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 hours ago
- Yahoo
Mass.-based burger chain to shut down more than two-thirds of its locations
It looks like Wahlbugers is hitting a wall. The nationwide burger chain, founded in Hingham by brothers Mark, Paul and Donnie Wahlberg, will close more than two-third of its locations, according to a report from Food Republic. The 79 locations that are shuttering belong to franchisee Hy-Vee Inc., a Midwestern supermarket chain that incorporated Wahlburgers kiosks in many of its stores as a replacement for its prior in-house dining option, Market Grille. Now, the chain plans to reintroduce Market Grille to its stores, according to Restaurant Business. The company's 2018 franchising deal with Hy-Vee was a significant component of its expansion. However, Wahlburgers CEO Randy Sharpe doesn't seem concerned about the development, as Hy-Vee comprised only a small portion of sales, according to Restaurant Business. 'We are growing restaurants,' Sharpe said in Restaurant Business' report. 'We're not going to be in the grocery business.' 'It's best that everyone stay in what their skill sets are and move on,' he added. The closures leave 34 locations, according to Food Republic, six of which are in Massachusetts: three in Boston (two within Boston Logan International Airport and one in the Fenway neighborhood), and one location each in Springfield, Plainville and Hingham. Outside of the United States, Wahlburgers has locations in Canada, New Zealand and Australia. The Wahlberg brothers founded Wahlburgers in 2011, and didn't expand to a second location – Toronto – until 2014. That same year, the family launched the reality TV program 'Wahlbugers,' which aired through 2019 and earned an Emmy nomination for 'Outstanding Unstructured Reality Program.' The latest from MassLive How Red Sox trade deadline strategy might be impacted by Marcelo Mayer's injury | Chris Cotillo Red Sox top draft pick (up to 99 mph) wants to make majors 'as fast as possible' Mookie Betts isn't in lineup vs. Red Sox on Friday, but here's when he'll be back Red Sox rookie still looking for answers on 'super annoying' wrist injury, return timeline Red Sox' Alex Cora explains promoting David Hamilton over Vaughn Grissom Read the original article on MassLive. Solve the daily Crossword
Yahoo
8 hours ago
- Yahoo
Haemonetics Builds Momentum with New Buy Rating and Growth Promise
Haemonetics Corporation (NYSE:HAE) is one of the . The company's stocks are upgraded to Buy despite a 9% decline in revenue, reported in the Q4 earnings call. A row of automated plasma collection devices in a modern laboratory. Headquartered in Massachusetts, Haemonetics Corporation (NYSE:HAE) is engaged in the development and supply of innovative medical technologies and systems for blood and plasma collection, surgical cell salvage, and hospital transfusion services. The company has a global reach with business operations in more than 50 countries. Its integrated solutions help improve procedural efficiency and patient care within leading hospitals. On May 8, 2025, Haemonetics Corporation (NYSE:HAE) released its Q4 2025 earnings report, which highlighted a 9% decline in revenue for the quarter and a 6% decline in fiscal 2025 due to the planned CSL transition. The revenue from the Blood Center in particular went down by 22%, while it is anticipated to decline by 23 to 26% in fiscal 2026 due to portfolio streaming. Following these results, Citi maintained a Hold rating on the stock with a price target of $71 on May 22, 2025. Later, on July 9, 2025, the company upgraded the stock from Hold to Buy rating and raised the price target to $90, reflecting faith in the company's growth potential. Haemonetics (NYSE:HAE) offers strong stability with a low beta of 0.40 and promising growth potential, projecting an 11.12% EPS increase over the next five years. While we acknowledge the potential of HAE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Metal Stocks with Insider Buying in 2025 and 10 Energy Stocks with Insider Buying in 2025 Disclosure. None. Erreur lors de la récupération des données Connectez-vous pour accéder à votre portefeuille Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données
Yahoo
8 hours ago
- Yahoo
Lantheus Holdings Expands Alzheimer's Diagnostics Despite Recent Stock Dip
Lantheus Holdings, Inc. (NASDAQ:LNTH) is one of the . The company completes the acquisition of Life Molecular Imaging Limited amid a fall in the monthly and weekly performance of shares. A medical professional performing a pulmonary function assessment on a patient. Lantheus Holdings, Inc. (NASDAQ:LNTH) is a Massachusetts-based company specializing in radiopharmaceuticals and diagnostic imaging. Through Lantheus Medical Imaging, Progenics, and EXINI, the company develops and commercializes precision diagnostics and radiotherapeutics used in oncology and cardiology. It is supported by strategic partnerships from global healthcare leaders. On July 21, 2025, Lantheus Holdings, Inc. (NASDAQ:LNTH) announced the completion of the acquisition of Life Molecular Imaging Limited. With the $350 million acquisition and the addition of Neuraceq, an F-18 PET imaging agent, Lantheus Holdings, Inc. (NASDAQ:LNTH) increases its capabilities in Alzheimer's disease diagnostics. On the other hand, the company's weekly and monthly performance were down by 10.98% and 8.65%, respectively. These declines follow the expiration of the company's transitional pass-through payment status for its product PYLARIFY and the subsequent implementation of the mean unit cost pricing for Medicare fee-for-service coverage. However, analysts, including Truist Financial and TD Cowen, stick to their Buy rating on the stock, signaling confidence in the company's future growth. Lantheus Holdings, Inc. (NASDAQ:LNTH) is anticipated to incur an 8.36% EPS growth in the next 5 years, and it currently has a low beta of 0.15, which makes the stock a good buy for investors seeking long term stocks with low risks. While we acknowledge the potential of LNTH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Metal Stocks with Insider Buying in 2025 and 10 Energy Stocks with Insider Buying in 2025 Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data